Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Torsten B Meissner, Ph.D.

Profile Picture

Torsten Meissner, PhD is an Assistant Professor of Surgery at Harvard Medical School with an appointment in the Division of Surgical Sciences at Beth Israel Deaconess Medical Center (BIDMC). The primary goal of his research is to create 'universal donor stem cells' that will resist immune rejection. Designed as 'off-the-shelf' products, ready for transplantation into any patient in need, such cells will be crucial to drive down the cost of production and thus democratize access to emerging cell therapies for indications such as type 1 diabetes (T1D), Parkinson's disease (PD), or macular degeneration (MD), where a particular cell type is lost over time and necessitates replacement with healthy tissue (StemJournal 2020; 2(1):1-5). Due to the paucity of donor material, stem cell-derived therapeutics grown in the laboratory are a promising alternative. A roadblock to these exciting new forms of treatment is immune rejection of the transplanted cells (Current Stem Cell Reports 2022; 8(4):206-218). During his postdoctoral work at the Harvard Stem Cell Institute Dr. Meissner has applied cutting-edge genome editing techniques to modify human pluripotent stem cell lines in order to protect them from immune rejection (PNAS 2019; 116:10441-10446). He has more than 15 years of experience in immunology, human pluripotent stem cell culture, cell differentiation, and genome editing. In 2019, Dr. Meissner joined the faculty of the Department of Surgery at BIDMC. In collaboration with the laboratory of Dr. Elliot Chaikof, MD PhD, he is developing hypoimmunogenic blood vessels from stem cell-derived building blocks that can be used as living 'off-the-shelf' products for vascular reconstruction.

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01EB032824 (MEISSNER TORSTEN B) Aug 5, 2022 - Apr 30, 2026
    Immunoevasive Engineered Living Blood Vessels
    Role: Co-Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
This operation might take several minutes to complete. Please do not close your browser.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Meissner's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (209)
Co-Authors (16)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.